Amarin announces senior management changes

Connecticut firm appoints ceo, president and principal accountant

Amarin Corporation, a US clinical-stage biopharmaceutical company with a focus on cardiovascular disease, has appointed Joseph Zakrzewski as chief executive. He will continue to serve as chairman of the board.

Zakrzewski has more than 20 years of experience, including holding the position of chief operating officer of Reliant Pharmaceuticals when Omacor/Lovaza was developed and acquired in 2007 by GlaxoSmithKline. He was most recently chief executive of Xcellerex, a Massachusetts-based biotechnology company. Although he currently serves on the boards of directors and in other advisory roles for various companies, Amarin is his primary business commitment.

Additionally, John Thero has been promoted to Amarin’s president. Since November 2009, he has been the company’s chief financial officer.

Prior to joining Amarin, Thero was chief financial officer at ViaCell, where he helped guide the sale of the company, and Abiomed, during its transition from a development-stage company into a commercial entity.

Colin Stewart, who was Amarin’s president and ceo, resigned last month to address personal matters.

In connection with these changes, Frederick Ahlholm, vice president finance, has become the company’s principal accounting officer.

You may also like

Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Manufacturing

Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market

Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Manufacturing

Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases

Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
Media

UK REACH reform falls short as industry warns of £500m+ compliance bill

The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
Manufacturing

Freudenberg Medical launches CleanAssure ISO Class 5 cleanroom service for sterile single-use biopharma assemblies

CleanAssure is an ISO Class 5 controlled cleanroom service delivering washed, dried and gamma-sterilised single-use assemblies to biopharmaceutical customers, addressing industry challenges around cleaning validation and contamination risk
Subscribe now